Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 04:05 am EDT
Share
Guangzhou LBP Medicine Science & Technology Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 327.08 million compared to CNY 264.64 million a year ago. Revenue was CNY 327.08 million compared to CNY 264.64 million a year ago. Net income was CNY 74.51 million compared to CNY 66.38 million a year ago. Basic earnings per share from continuing operations was CNY 0.8 compared to CNY 0.91 a year ago. Diluted earnings per share from continuing operations was CNY 0.8 compared to CNY 0.91 a year ago.
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Companyâs main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY CO., LTD. 